Search Results - "Germà Lluch, José Ramón"

Refine Results
  1. 1
  2. 2

    Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain by Llort, Gemma, Muñoz, Carmen Yagüe, Tuser, Mercè Peris, Guillermo, Ignacio Blanco, Lluch, José Ramón Germà, Bale, Allen E., Franco, Mayra Alvarez

    Published in Human mutation (01-03-2002)
    “…BRCA1 and BRCA2 mutations underlie a substantial proportion of all hereditary breast cancer. The mutational spectrum in these genes is very broad, with…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    The PDGFRβ-AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors by JULIACHS, M, MUNOZ, C, VINALS, F, MOUTINHO, C. A, VIDAL, A, CONDOM, E, ESTELLER, M, GRAUPERA, M, CASANOVAS, O, GERMA, J. R, VILLANUEVA, A

    Published in Clinical cancer research (01-02-2014)
    “…We examined whether PI3K-AKT or extracellular signal-regulated kinase (ERK) signaling pathways could play a role in the development of cisplatin (CDDP)…”
    Get full text
    Journal Article
  6. 6

    The impact of KRAS mutations on VEGF-A production and tumour vascular network by Figueras, Agnès, Arbos, Maria Antonia, Quiles, Maria Teresa, Viñals, Francesc, Germà, Josep Ramón, Capellà, Gabriel

    Published in BMC cancer (18-03-2013)
    “…The malignant potential of tumour cells may be influenced by the molecular nature of KRAS mutations being codon 13 mutations less aggressive than codon 12…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors by Juliachs, Mercè, Vidal, August, Del Muro, Xavier Garcia, Piulats, Josep M, Condom, Enric, Casanovas, Oriol, Graupera, Mariona, Germà, Jose R, Villanueva, Alberto, Viñals, Francesc

    Published in BMC cancer (10-08-2013)
    “…Cisplatin (CDDP) resistance in testicular germ cell tumors (GCTs) is still a clinical challenge, and one associated with poor prognosis. The purpose of this…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14

    The impact of KRAS mutations on VEGF-A production and tumour vascular network by Figueras i Amat, Agnès, Arbós i Via, Maria Antònia, Quiles, Maria Teresa, Viñals Canals, Francesc, Germà Lluch, José Ramón, Capellá, G. (Gabriel)

    Published in BMC cancer (18-03-2013)
    “…Background: The malignant potential of tumour cells may be influenced by the molecular nature of KRAS mutations being codon 13 mutations less aggressive than…”
    Get full text
    Journal Article
  15. 15

    ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor by Juliachs, M., Castillo‐Ávila, W., Vidal, A., Piulats, J.M., Garcia del Muro, X., Condom, E., Hernández‐Losa, J., Teixidó, C., Pandiella, A., Graupera, M., Casanovas, O., Germà, J.R., Villanueva, A., Viñals, F.

    Published in International journal of cancer (01-07-2013)
    “…In this work, we have analyzed the expression of different members of the ErbB family in human samples of testicular germ cell tumors (GCTs). We observed…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours by ZURITA, A. J, DIESTRA, J. E, CONDOM, E, GARCIA DEL MURO, X, SCHEFFER, G. L, SCHEPER, R. J, PEREZ, J, GERMA-LLUCH, J. R, IZQUIERDO, M. A

    Published in British journal of cancer (24-03-2003)
    “…This study was undertaken to investigate the expression and predictive value for outcome of multidrug resistance-associated (MDR) proteins P-glycoprotein…”
    Get full text
    Journal Article
  18. 18

    Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer by GARCIA DEL MURO, X, MARCUELLO, E, GUMA, J, PAZ-ARES, L, CLIMENT, M. A, CARLES, J, SANCHEZ PARRA, M, TISAIRE, J. L, MAROTO, P. JR, GERMA, J. R

    Published in British journal of cancer (01-02-2002)
    “…A multicentre phase II trial was undertaken to evaluate the activity and toxicity of docetaxel plus cisplatin as first-line chemotherapy in patients with…”
    Get full text
    Journal Article
  19. 19

    Survival results in five malignant neoplasms separated by a decade at Institut Català d’Oncologia, Spain by Germá-Lluch, José Ramón, Petriz, Lourdes, Lopez, Pau, Asensio, Esther

    Published in Medicina clínica (English ed.) (23-02-2018)
    “…Five years’ data relative survival (RS) is presented in 3 solid tumours: breast, colorectal (CRC) and lung and 2 haematologic neoplasms: large B cell lymphoma…”
    Get full text
    Journal Article
  20. 20